One of five palm trees planted in Gainesville as a memorial to the 1990 student murder victims appears to have died from lethal bronzing. The Florida Department of Transportation will likely ...

PENDER COUNTY, N.C. (WECT) - Pender County Mosquito Control is preparing for treatments for the season and is asking beekeepers in the county to help protect their bees. Beekeepers should register the ...

WE’LL SEE HIGH PRESSURE IN CONTROL OF OUR WEATHER. AND THAT’S YOUR NEW The Palm Beaches are now firmly on the culinary map after nine local restaurants were recognized in the 2025 Florida ...

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

YOU’RE TAKING A LIVE LOOK RIGHT NOW OVER CENTENNIAL SQUARE IN DOWNTOWN WEST PALM BEACH. THE GREEN MARKET IS HEADING INTO ITS FINAL DAYS OF THE SEASON. YOU ONLY HAVE TWO MORE WEEKENDS TO ATTEND.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for treating adults and adolescents aged 12 and older with chronic spontaneous urticaria (CSU) who continue to ...

One came in 2023, however, when the FDA rejected it as a treatment for chronic spontaneous urticaria (CSU), asking for more data. Eighteen months later—and backed by more conclusive results ...

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and ...

“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives,” said ...

Phase 3 trials showed significant reductions in itch and urticaria severity with dupilumab compared to placebo at week 24. Dupilumab offers a new treatment option for CSU, being the first targeted ...

Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older. Several studies reported reduced itch severity and urticaria activity with dupilumab.